CA
REGN icon

Centerpoint Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Centerpoint Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$8K – 565
2023
Q3 		$8K Hold
10
– – ﹤0.01% 351
2023
Q2 		$7K Hold
10
– – ﹤0.01% 372
2023
Q1 		$8K Buy
10
+2
+25% +$1.51K ﹤0.01% 367
2022
Q4 		$6K Hold
8
– – ﹤0.01% 344
2022
Q3 		$6K Hold
8
– – ﹤0.01% 255
2022
Q2 		$5K Hold
8
– – ﹤0.01% 275
2022
Q1 		$6K Hold
8
– – ﹤0.01% 266
2021
Q4 		$5K Buy
+8
New +$4.92K ﹤0.01% 273
2020
Q3 		– Sell
-24
Closed -$15K – 268
2020
Q2 		$15K Buy
+24
New +$13.6K 0.01% 138
2019
Q1 		– Sell
-55
Closed -$21K – 263
2018
Q4 		$21K Hold
55
– – 0.02% 127
2018
Q3 		$22K Hold
55
– – 0.02% 130
2018
Q2 		$19K Hold
55
– – 0.02% 146
2018
Q1 		$19K Hold
55
– – 0.02% 136
2017
Q4 		$21K Buy
+55
New +$22.3K 0.02% 115

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Centerpoint Advisors's REGN Position: Q4 2023 in Review

Centerpoint Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 10 shares — an estimated $8K sold.

Centerpoint Advisors first reported a position in REGN in Q4 2017 and held it in 14 quarters. The position peaked at $22K in Q3 2018. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

  • Centerpoint Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centerpoint Advisors sold 10 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $8K.
  • Centerpoint Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 14 quarters.
  • Centerpoint Advisors's Regeneron Pharmaceuticals position peaked at $22K in Q3 2018.
  • 1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Centerpoint Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.